Clinical Trial

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-05
Trial Details
NCT Number NCT06742892
Lead Sponsor Shanghai Henlius Biotech
Conditions Carcinoma, Hepatocellular
Enrollment 90 participants
Start Date 2025-03-03
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-06-05 (estimated)
Updated on ClinicalTrials.gov 2025-03-10